Bikaner
Bikaner
Bikaner, Rajasthan, India15 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | cardiovascular disorder, heart disorder, heart failure | Active, not recruiting | Phase 3 | 2026-10-01 | NCT06200207 | |
| Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage | Hemorrhage, Intracranial Hemorrhages, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, intracerebral hemorrhage, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-24 | NCT07243704 | |
| Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Dyslipidemias, Infarction, Lipid Metabolism Disorders, Necrosis, Non-ST Elevated Myocardial Infarction, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, ST-elevation myocardial infarction, acute coronary syndrome, cardiovascular disorder, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Phase 3 | 2026-09-16 | NCT07102628 | |
| ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | Acute Myocardial Infarction (AMI); Cardiovascular Risk | Active, not recruiting | Phase 3 | 2026-09-09 | NCT06118281 | |
| An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-04 | NCT07517263 | |
| A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05739383 | |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | cardiovascular disorder | Active, not recruiting | Phase 3 | 2026-08-31 | NCT05669755 | |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT05030428 | |
| Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Active, not recruiting | Phase 3 | 2026-08-19 | NCT06042478 | |
| A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. | Advanced Solid Tumors | Recruiting | Phase 1 | 2026-07-28 | NCT07042100 | |
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | Chronic Disease, Disease Attributes, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bronchial disorder, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, pneumonia, pulmonary emphysema, respiratory system disorder, respiratory tract infectious disorder | Active, not recruiting | Phase 2 | 2026-07-20 | NCT06981078 | |
| A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age. | Alphavirus infectious disease, Infections, Mosquito-Borne Diseases, RNA Virus Infections, Togaviridae infectious disease, arbovirus infection, chikungunya, vector-borne disease, viral infectious disease | Recruiting | Phase 2 / Phase 3 | 2026-04-29 | NCT07555392 | |
| A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER) | Symptomatic Obstructive Hypertrophic Cardiomyopathy | Active, not recruiting | Phase 4 | 2026-04-28 | NCT07004972 | |
| Indian Trial of Tranexamic Acid in Spontaneous Intracerebral Haemorrhage | Intracerebral Hemorrhagic Stroke, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hemorrhagic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 4 | 2026-01-22 | NCT05836831 | |
| A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium | Conjunctival Diseases, eye disorder, pterygium | Active, not recruiting | Phase 3 | 2025-09-24 | NCT05456425 |